espite widespread criticism, a new report finds the Food and Drug Administration made useful changes to a controversial program that provides access to experimental medicines. However, the agency still needs to do a better job of explaining how patient side effect data can influence drug approval decisions, according to the U.S. Government Accountability Office analysis.

Not surprisingly, the findings prompted the same sort of bickering sparked by the program, itself.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.